Spots Global Cancer Trial Database for Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Official Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (ECHO-202/KEYNOTE-037)
Study ID: NCT02178722
Conditions
Study Description
Brief Summary: The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
The Angeles Clinic and Research Institute, Los Angeles, California, United States
US Davis Cancer Center, Sacramento, California, United States
University Of Colorado Cancer Center, Aurora, Colorado, United States
University of Connecticut Health Center Carole And Ray Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
Miami Cancer Institute at Baptist Health, Inc, Miami, Florida, United States
Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, Georgia, United States
The University of Chicago Medicine, Chicago, Illinois, United States
St. Francis Cancer Center, Topeka, Kansas, United States
Greater Baltimore Cancer Center, Baltimore, Maryland, United States
St. Agnes Hospital Cancer Institute, Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders (RCCA MD LLC- Maryland Division), Bethesda, Maryland, United States
University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States
Health Partners Institute, Saint Louis Park, Minnesota, United States
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
The Christ Hospital Hematology Oncology, Lindner Research Center, Cincinnati, Ohio, United States
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
West Cancer Center, Germantown, Tennessee, United States
Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee, United States
University Of Texas Southwestern Medical Center At Dallas, Dallas, Texas, United States
Virginia Cancer Specialists, Arlington, Virginia, United States
Contact Details
Name: Mark Jones, MD
Affiliation: Incyte Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
